Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04562870 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 2, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv28
  2. Primary and study completion dates: Jan 6, 2025 to Sep 2026v27
  3. Site details revised at 1 of 21 sitesv26
  4. Eligibility criteria shortened, about 1 word Study title shortened, about 4 wordsv25 Show 1 more changeShow less
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Primary endpoint revised Secondary endpoints revised (11)v24 Show 1 more changeShow less
    • Secondary endpoints revised (11)

    See this version in full on ClinicalTrials.gov ↗

Show 22 earlier versionsHide 22 earlier versions
  1. Study sites: 22 to 21v23
  2. Re-verified, no change to tracked fieldsv22
  3. Study sites: 19 to 22v21
  4. Study sites: 42 to 19v20
  5. Primary and study completion dates: May 31, 2023 to Jan 6, 2025 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 42 of 42 sitesv19 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 42 of 42 sites
  6. Study sites: 40 to 42v18
  7. Study sites: 34 to 40v17
  8. Study sites: 30 to 34v16
  9. Study sites: 27 to 30v15
  10. Study sites: 25 to 27v14
  11. Study sites: 23 to 25v13
  12. Study sites: 15 to 23 Eligibility criteria expanded, about 63 wordsv12 Show 1 more changeShow less
    • Eligibility criteria expanded, about 63 words

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites: 13 to 15v11
  14. Study sites: 12 to 13v10
  15. Study sites: 9 to 12v9
  16. Study sites: 4 to 9v8
  17. Study sites: 3 to 4v7
  18. Study sites: 2 to 3v6
  19. Study sites: 1 to 2v5
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 2021 to Mar 17, 2021v4 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2021 to Mar 17, 2021
  21. Enrollment target: 138 to 112 Start date: Mar 2021 to Apr 2021 · Eligibility criteria expanded, about 66 words · Secondary endpoints revised (11) · 1 morev3 Show 4 more changesShow less
    • Start date: Mar 2021 to Apr 2021
    • Eligibility criteria expanded, about 66 words
    • Secondary endpoints revised (11)
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  22. Start date: Oct 30, 2020 to Mar 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.
Trial Details
NCT Number NCT04562870
Lead Sponsor Karyopharm Therapeutics Inc
Conditions Myelofibrosis
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov